首页> 外文OA文献 >Mesenchymal stromal cells as vehicles of tetravalent bispecific Tandab (CD3/CD19) for the treatment of B cell lymphoma combined with IDO pathway inhibitor d-1-methyl-tryptophan

【2h】

Mesenchymal stromal cells as vehicles of tetravalent bispecific Tandab (CD3/CD19) for the treatment of B cell lymphoma combined with IDO pathway inhibitor d-1-methyl-tryptophan

机译：间充质基质细胞作为四价双特异性Tandab（CD3 / CD19）载体，用于治疗B细胞淋巴瘤并结合IDO途径抑制剂d-1-甲基色氨酸

代理获取

本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。

页面导航

著录项
引文网络
相似文献
相关主题

著录项

作者
Xiaolong Zhang; Yuanyuan Yang; Leisheng Zhang; Yang Lu; Qing Zhang; Dongmei Fan; Yizhi Zhang; Yanjun Zhang; Zhou Ye; Dongsheng Xiong;
展开▼
作者单位

展开▼
年度 2017
总页数
原文格式 PDF
正文语种
中图分类

相似文献

外文文献
中文文献
专利

1. Mesenchymal stromal cells as vehicles of tetravalent bispecific Tandab (CD3/CD19) for the treatment of B cell lymphoma combined with IDO pathway inhibitor d-1-methyl-tryptophan [J] . Xiaolong Zhang, Yuanyuan Yang, Leisheng Zhang, Journal of Hematology and Oncology . 2017,第1期

机译：间充质基质细胞作为四价双特异性Tandab（CD3 / CD19）的媒介物，用于治疗B细胞淋巴瘤并结合IDO途径抑制剂d-1-甲基色氨酸
2. T and NK cells of B cell NHL patients exert cytotoxicity against lymphoma cells following binding of bispecific tetravalent antibody CD19 × CD3 or CD19 × CD16 [J] . P?rtnerL.M., Sch?nbergK., HejaziM., Cancer immunology, immunotherapy : . 2012,第10期

机译：B细胞NHL患者的T细胞和NK细胞在结合双特异性四价抗体CD19×CD3或CD19×CD16后对淋巴瘤细胞产生细胞毒性
3. T and NK cells of B cell NHL patients exert cytotoxicity against lymphoma cells following binding of bispecific tetravalent antibody CD19 × CD3 or CD19 × CD16 [J] . Lisa M. Pörtner, Kathrin Schönberg, Maryam Hejazi, Cancer Immunology, Immunotherapy . 2012,第10期

机译：B细胞NHL患者的T细胞和NK细胞在结合双特异性四价抗体CD19×CD3或CD19×CD16后对淋巴瘤细胞产生细胞毒性
4. A CD19/CD3 Bispecific TandAb, AFM11, Recruits T Cells to Potently and Safely Kill CD19+ Tumor Cells in Pre-Clinical Models [C] . Uwe Reusch, Stefan Knackmuss, Kristina Ellwanger, PEGS . 2014

机译：CD19 / CD3双特异性TANDAB，AFM11，在临床前模型中促进T细胞才能效果，安全地杀死CD19 +肿瘤细胞
5. Comparative pharmacology of the human CD19/CD3 Bispecific T-cell engager (BiTERTM) antibody blinatumomab with the hybrid murine surrogate CD19/CD3 BiTE antibody hyS103. [D] . Fuhrmann, Stacy R. 2010

机译：人CD19 / CD3双特异性T细胞衔接子（BiTERTM）抗体blinatumomab与杂种鼠替代CD19 / CD3 BiTE抗体hyS103的比较药理学。
6. Mesenchymal stromal cells as vehicles of tetravalent bispecific Tandab (CD3/CD19) for the treatment of B cell lymphoma combined with IDO pathway inhibitor d-1-methyl-tryptophan [O] . Xiaolong Zhang, Yuanyuan Yang, Leisheng Zhang, 2017

机译：间充质基质细胞作为四价双特异性Tandab（CD3 / CD19）载体用于治疗B细胞淋巴瘤并结合IDO途径抑制剂d-1-甲基色氨酸
7. Mesenchymal stromal cells as vehicles of tetravalent bispecific Tandab (CD3/CD19) for the treatment of B cell lymphoma combined with IDO pathway inhibitor d-1-methyl-tryptophan [O] . Xiaolong Zhang, Yuanyuan Yang, Leisheng Zhang, 2017

机译：间充质基质细胞作为四价双特异性Tandab（CD3 / CD19）的载体，用于治疗B细胞淋巴瘤和IDO途径抑制剂d-1-甲基色氨酸

Mesenchymal stromal cells as vehicles of tetravalent bispecific Tandab (CD3/CD19) for the treatment of B cell lymphoma combined with IDO pathway inhibitor d-1-methyl-tryptophan

著录项

引文网络

相似文献

相关主题

期刊订阅